Phase IIb AMP Studies: In Vitro Susceptibility of HIV-1 Isolates to Broadly Neutralizing Antibody VRC01 Predicts HIV Prevention Efficacy in MSM, Transgender Persons, and Cisgender Women

Clinical Care Options (CCO) presents expert faculty discussing the barriers and solutions to expanding PrEP uptake, from a nursing perspective

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Christopher Fox, MSN, RN, ANP-BC, AAHIVS Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2022 Expired: June 13, 2023

Dr Michelle Collins-Ogle and Clinical Care Options (CCO): HIV postexposure prophylaxis is recommended following a potential sexual exposure.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 26, 2022

Clinical Care Options (CCO): expert commentary on major findings from EPIC-NSW and next steps in PrEP strategies and populationwide HIV prevention efforts

Prof. Don Smith Released: March 18, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): There are key management considerations for patients initiating LA cabotegravir for PrEP

Jason Schafer, PharmD, MPH Released: March 15, 2022